# A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

> **NCT00552929** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 102 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT00552929
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-04
- **Primary completion:** 2006-09-15
- **Final completion:** 2006-09-15
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552929, "A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00552929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*